ABO

Across TCGA pan-cancer cohorts, ABO mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABO data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ABO mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ABO expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ABO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.794	.010	9	view →
PDAC	OS	Quartile	All	0.396	0.664	.031	6	view →
LUAD	DFS	Quartile	III,IV	0.330	0.986	.038	3	view →
HNSC	OS	Quartile	IV	0.924	0.622	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ABO–CCRCC (OS)

Open the CCRCC breakdown →